BioRestorative Therapies, Inc. ("BRT" or the "Company")
(OTCBB:BRTX), a life sciences company focused on adult stem
cell-based therapies for various personal medical applications, today
announced that it has entered into a two-year collaborative Research
Agreement (“Agreement”) with Pfizer Inc. (“Pfizer”) to study human brown
adipose tissue and cell lines.
Under the terms of the Agreement, BRT and Pfizer will jointly conduct a
study titled “Development and Validation of a Human Brown Adipose
Cell Model,” which will seek to further characterize the identity
and metabolic function of these cell lines. BRT has accumulated a large
collection of human brown adipose tissue samples, preadipocyte cell
lines and immortalized cell lines for use in potentially developing a
cell therapy product. The results of the research may be used by both
companies.
Mark Weinreb, Chief Executive Officer of BRT, said, “Pfizer is a global
pharmaceutical leader and we are very excited to be working with it on
our ThermoStem® program. Research into human brown fat to date has
suggested that brown fat is correlated with the maintenance and
regulation of metabolism. Ultimately, we will look to determine if our
cell lines have utility in the treatment of obesity, which is
responsible for many diseases, including type 2 diabetes. We look
forward to a productive research project for both our companies.”
About BRT’s ThermoStem® Program
Brown fat is a population of adipose (fat) tissue found in the human
body and plays a key role in the evolutionarily conserved mechanisms
underlying energy homeostasis in mammals. Human newborns and hibernating
mammals have high levels of brown fat and its main function is to
generate body heat and regulate metabolism. Recent studies have
demonstrated that brown fat is present in the adult human body and may
be correlated with the maintenance and regulation of metabolism.
In June 2011, BRT launched the initial research phase of what it
believes will develop into a technology that involves the use of brown
fat in a cell-based therapeutic program referred to as the ThermoStem®
Program. The ThermoStem® Program will focus on treatments for
type 2 diabetes and obesity, as well as for hypertension, other
metabolic disorders and cardiac deficiencies, and will involve the study
of stem cells, several genes, proteins and/or mechanisms that are
related to these diseases and disorders.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com)
develops products and medical procedures using cell and tissue
protocols, primarily involving adult stem cells, including:
-
brtxDISC™ (Disc Implanted Stem Cells)
is an investigational non-surgical treatment for protruding, bulging
and herniated lumbar discs that is intended for patients who have
failed non-invasive procedures and face the prospect of surgery. The
treatment involves culturing a patient’s own stem cells and then
delivering them via a proprietary medical device to the damaged region
of the disc in an outpatient procedure.
-
ThermoStem® is a treatment using brown fat stem cells that is
under development for metabolic disorders including diabetes and
obesity. Initial preclinical research indicates that increased amounts
of brown fat in the body may be responsible for additional caloric
burning as well as reduced glucose and lipid levels.
-
brtx-C Cosmetic is based on the development of a human cellular
extract that has been demonstrated in in vitro skin studies to
increase the production of collagen and fibronectin, which are
proteins that are essential to combating the aging of skin. Potential
cosmetic uses are being explored with third parties.
The Company also offers plant stem cell-based facial creams and beauty
products under the Stem Pearls® brand at www.stempearls.com.
This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, and such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. You
are cautioned that such statements are subject to a multitude of risks
and uncertainties that could cause future circumstances, events or
results to differ materially from those projected in the forward-looking
statements as a result of various factors and other risks, including
those set forth in the Company's Form 10-K filed with the Securities and
Exchange Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue reliance
on such statements. The forward-looking statements in this release are
made as of the date hereof and the Company undertakes no obligation to
update such statements.
Copyright Business Wire 2014